A Medical Testing Lab in
the Palm of Your Hand™
A Regulation A+ Investment
Price per Share of Common
111 Shares / $499.50
Number of Share Holders
Total Capital Raised*
The Check4 platform by IdentifySensors represents a technological breakthrough, which electronically pinpoints genetic material of targeted pathogens in saliva. This portable self-test produces a digital signal that is analyzed in the cloud in less than three minutes with accuracy and sensitivity greater than PCR tests.
Solid-state electrodes enable almost instantaneous results without lab work, chemical reagents or amplification. In July 2022, the company partnered with Jabil Healthcare to optimize the technology for mass manufacturing.
The company expects FDA approval later this year, with large-scale manufacturing to follow soon after. IdentifySensors intends to significantly disrupt the diagnostics industry for multiple pathogens and realize substantial profits by 2023.
Completely New Technology
How is Check4™ different from other pathogen tests?
The Pandemic has taught the public much about medical testing, its limitations and effectiveness. Check4™ by IdentifySensors, is not a PCR test, an antibody test or an antigen test. These are all outdated technologies developed 50 years ago, yet they still make up the vast majority of testing for infectious diseases today.
Check4™ is new patented technology that moves medical testing from a chemical reaction to a digital readout. It uses electronic pulses to measure precise levels of micro-electric currents that pass through viruses and bacteria. Each pathogen carries a digital signature, which is quickly identified in saliva and decoded through a small portable reader. When used, the reader transmits results wirelessly to the user’s smartphone in minutes.
In July 2022, this proprietary and patented technology moved from development stages while at Purdue University to the manufacturing stage with Jabil Healthcare. Soon, new devices will be manufactured by the millions for governments, health care systems and corporations.
Fast & Accurate Saliva Self-Test
Our Team Worked in Partnership with Purdue University
All New Nanosensor Technology
Results Available In Minutes
iOS & Android Compatible
Protected by 5 Patents
Ready to invest?
In Partnership with Purdue University
When IdentifySensors developed the concept for digital disease testing, the company knew it needed a world-class academic institution to verify the discovery and help move the technology to commercialization.
In 2019, IdentifySensors partnered with the world-renowned Department of Inflammation, Immunology and Infectious Diseases at Purdue University.
In the spring of 2021, IdentifySensors moved the technology from the research lab to the commercialization stage, where the work at Purdue is being optimized for large-scale, roll-to-roll manufacturing.
In the summer of 2022, IdentifySensors completed its proof of concept and partnered with Jabil Healthcare to optimize the manufacturing process. The company intends to be awarded FDA approval later in 2023.
Proprietary and Patented Technology
Years ago, IdentifySensors began developing and patenting nanosensors that detect pathogens that grow in food during long-distance transport. When the pandemic struck, scientists turned their research to a rapid COVID test based on the same technology.
Soon into the development stage, researchers realized the technology could serve as an all-new disruptive platform that could forever change the medical testing industry. Check4™ currently has several utility patents, with others pending.
Why this Breakthrough is Significant
IdentifySensors Biologic’s researchers have developed a new and disruptive nanosensor technology that rapidly detects COVID-19 and the multiple variants, and intends to develop multiplexed tests as well for influenza. Other intended pathogens include mumps, measles, MRSA, Hep C & B, HIV, foodborne pathogens, and more.
Benefits of Accurate Rapid Home Testing for Multiple Diseases
- Immediate home results without a prescription or doctor’s visit
- More frequent home testing will promote earlier detection
- Earlier treatment for improved health outcomes
- Lower costs for individuals and health-care providers
- Reduced transmission rates of infectious diseases
- Increased health-care efficiencies and use of telemedicine
- Improved population health
- Higher safety for health care workers
- Greater access to testing and early treatment in developing nations
- Real time observation of any future pandemic
Results In Hand
What does IdentifySensors Biologics do?
Check4™ is intended to be a fast, accurate and affordable saliva self-test for COVID-19 and a host of other infections. Results are displayed within minutes on a smartphone app, with accuracy that far exceeds current rapid home tests.
How is Check4-COVID different from all other COVID tests?
Do healthcare professionals need to administer the test?
How does the test work?
How accurate is Check4-COVID™?
Why does the test notify health authorities?
Why does the test use a smartphone app?
What if I don’t have a smartphone?
Do I have to buy multiple devices to test other family members?
Is the Smartphone app HIPAA compliant? What happens to my personal information?
Can I turn off the reporting function of the app?
How much will the test cost?
How can I be sure the test is accurate?
What is the problem with current rapid tests?
When will the test be available to consumers?
Where will the test be sold?
Can the test be used to minimize quarantine times?
Is the test technology patented?
When will the product be available on the market?
How long will the FDA approval process take?
What other virus and bacteria can Check4 detect?
How Your Investment Will Be Put to Work
The next step is to refine the designs for efficient large-scale commercialization and manufacturing. Your investment will help manufacture millions of Check4™ readers and test cartridges and help bring them to market soon.